Site plate · Europe
- Company
- PolyPeptide Group AG; buyer Samsung Biologics through Samsung Peptide AG
- Site
- Baar, Switzerland
- Money
- CHF 1.46 billion
- Makes
- Six GMP sites in Europe, the US and India; Malmö SPPS doubling in commissioning, Strasbourg ramp up in H2 2026; total peptide volume not disclosed
- Online
- Now
AnnouncedBuildingRunning
B4Deals
PolyPeptide Samsung board slate approved while settlement waits on clearances
PolyPeptide shareholders elected five directors led by Samsung Biologics chief John Rim and removed share transfer and voting limits. Both steps take effect only at settlement, now expected at the end of 2026 or in early 2027.
In one linePolyPeptide shareholders elected a five member board chaired by Samsung Biologics CEO John Rim and removed transfer and voting limits, both effective only at settlement of the CHF 44.31 per share offer.
